Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced today the appointment of Adam Townsend as Chief Commercial Officer. We are incredibly pleased to welcome Adam to Apellis’ leadership team. Adam has a wealth of knowledge and expertise in bringing novel therapies to market and has worked with a number of leading organizations in the US, Europe and the UK,” said Cedric Francois, MD, PhD, founder and chief executive officer of Apellis. “His experience leading the recent launches of Tecfidera® and Spinraza® while at Biogen, and his proven success in marketing and commercializing innovative therapies, will be invaluable as we prepare to build our commercial franchises in paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy (GA), followed by other complement-mediated conditions in the future
November 20, 2018
More posts by Stacey Lerner
Recent posts from Park Square Executive Search
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at firstname.lastname@example.org